Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.
Clinical trial NCT03130881 · UNKNOWN
Trial details
- NCT number
- NCT03130881
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-08
- Primary completion
- 2020-12-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.